Tag: HistoSonics
First-in-human CAIN trial demonstrates feasibility of histotripsy for small renal tumours
First-in-human results of the CAIN trial evaluating the HistoSonics system for the treatment of primary renal cancer have demonstrated that histotripsy can be used...
HistoSonics’s #HOPE4KIDNEY trial completes patient enrolment
HistoSonics has announced that it has completed enrolment in a pivotal trial to evaluate its histotripsy platform in treating kidney tumours.
The US company’s prospective,...
Histotripsy: What we know so far
Histotripsy is a non-thermal, non-ionising and non-invasive focused ultrasound technique which relies on cavitation for mechanical tissue breakdown at the focal point. Leading research...
HistoSonics launches first histotripsy programmes in Hong Kong
HistoSonics has announced the company’s initial partnership in Asia with Hong Kong University receiving their first histotripsy system following a donation from the Li...
First patient treated with HistoSonics Edison histotripsy system
HistoSonics, developer of a non-invasive platform and sonic beam therapy called histotripsy, has announced the treatment of the first patient in its pivotal #HOPE4KIDNEY...
HistoSonics receives FDA clearance for Edison histotripsy system
HistoSonics, the manufacturer of the Edison System and novel histotripsy therapy platforms, has announced the marketing authorisation of its “breakthrough” platform via the...
#HOPE4LIVER trial demonstrates safety and efficacy of histotripsy for liver tumours
The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2023 annual meeting (9–13 September, Copenhagen, Denmark) played host to another FIRST@CIRSE session, which saw...
HistoSonics announces first kidney tumour treatment using histotripsy
HistoSonics has announced the first kidney patient has been treated using its histotripsy platform. The procedure was performed at the Leeds Teaching Hospitals NHS...
HistoSonics receives FDA breakthrough device designation for novel sonic beam therapy
HistoSonics has revealed that the US Food and Drug Administration (FDA) has granted the company breakthrough device designation for its new histotripsy targeted liver...
